title: Acetylsalicylic acid decreases the labeling of blood constituents with technetium-99M.
abstract: Acetylsalicylic acid is the most widely used drug as antipyretic, analgesic, anti-inflammatory agent and for secondary prevention of thrombotic phenomena in the heart, brain and peripheral circulation. Drugs can modify the labeling of blood constituents with technetium-99m (99mTc). This work has evaluated the effect of in vivo treatment with acetylsalicylic acid on the in vitro labeling of the blood constituents with 99mTc. Wistar rats were treated with different doses (1.5, 3.0 and 6.0 mg/kg) of acetylsalicylic acid during 1 hour. At higher dose used (6.0 mg/kg) animals were treated during different period of time (0.25, 1.0 and 4.0 hours). Animals treated with physiologic saline solution were used as control. After the labeled process; plasma (P), blood cells (BC), insoluble (IF-P, IF-BC) and soluble (SF-P, SF-BC) fractions were separated. Afterwards, the percentage of radioactivity (%ATI) in each fraction was calculated. The treatment during 1 hour with acetylsalicylic acid at higher dose has significantly (p < 0.05) modified the fixation of 99mTc on blood cells. Considering the results, we suggest that acetylsalicylic acid used at therapeutic doses may interfere with the nuclear medicine procedures related to these blood constituents.
authors.affiliation: Departamento de Farmacologia e Psicobiologia, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil. adenilso@uerj.br
authors.forename: A S
authors.initials: AS
authors.lastname: Fonseca
authors.forename: J N G
authors.initials: JN
authors.lastname: Frydman
authors.forename: Vanessa C
authors.initials: VC
authors.lastname: Rocha
authors.forename: M
authors.initials: M
authors.lastname: Bernardo-Filho
mesh_terms: D000818:Animals; D001241:Aspirin / Q000494:pharmacology*; D001773:Blood Cells / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D008297:Male; D009683:Nuclear Medicine / Q000379:methods; D010950:Plasma Cells / Q000187:drug effects / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011877:Radionuclide Imaging; D051381:Rats; D017208:Rats, Wistar; D015203:Reproducibility of Results; D013667:Technetium / Q000378:metabolism*; D013997:Time Factors
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D013667:Technetium; D001241:Aspirin